Akari Therapeutics Plc (AKTX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 29, 2026, Akari Therapeutics, Plc (the “ Company ”), entered into an amendment (the “ CEO Agreement Amendment
How this was made
The 30-second read
Why it matters
The compensation increase represents a material change in the company's cost structure and may affect investor perception of management incentives.
Market read
First disclosure of executive pay raise; modest impact expected on AKTX share price.
What to watch
The RSU grant is contingent on shareholder approval of plan amendment, which may not materialize.
Background
Akari Therapeutics Plc (AKTX) filed a Form 8‑K reporting amendments to its CEO employment agreement, including salary and equity compensation changes.
Ticker impact
SEC 8‑K filing discloses a CEO agreement amendment increasing base salary, bonus target and RSU grant for Akari Therapeutics.
likely slight downward pressure as investors price higher compensation expense
The filing is the first public disclosure of the pay raise; such executive compensation changes typically have modest negative impact on share price.
Market effects
Limited; may signal higher cost structure for biotech firms with similar compensation practices.
None
Low
Counterpoint
Higher CEO pay could align incentives and drive execution, potentially supporting upside if milestones are met.
Key entities
- companyAkari Therapeutics Plc
Biotech company listed on NASDAQ under ticker AKTX.
- personAbizer Gaslightwala
Chief Executive Officer of Akari Therapeutics.
